




**Fig. S1. LDL-C levels at baseline and week 12 for each participant with both baseline and week 12 LDL-C measurements.** The dashed line indicates the boundary for 50% reduction from baseline to week 12 in LDL-C levels. LDL-C = low density lipoprotein cholesterol; Q2W = every 2 weeks; Q4W = every 4 weeks.



**Fig. S2. Subgroup analysis on percent change from baseline to week 12 in LDL-C levels.** BMI = body mass index; CFB = change from baseline; CI = confidence interval; ETD = estimated treatment difference; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low density lipoprotein cholesterol; LS = least squares; NA = not available; Q2W = every 2 weeks; Q4W = every 4 weeks.



**Fig. S3. Percent change from baseline at week 12 in LDL-C levels for each tafocimab-treated participant by *LDLR* variant pathogenicity.** LDL-C = low density lipoprotein cholesterol; Q2W = every 2 weeks; Q4W = every 4 weeks.



**Fig. S4. Baseline and 12-week change in lipids and PCSK9 levels by *LDLR* variant pathogenicity.** LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; IQR = interquartile range; non-HDL-C = non-high density lipoprotein cholesterol; vLDL-C = very low density lipoprotein cholesterol; SD = standard deviation; SE = standard error.